People · Operator
Named in public records as an officer, director or promoter · active 2008–2012 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Selexys Pharmaceuticals Corp | — | Biotechnology | Series C | $89.1M | $1.8B | 2008 |
David Falconer at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Falconer on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Todd Foley | 1 | 12 |
| Tom Walker | 1 | 7 |
| William Paiva | 1 | 6 |
| Philip Jones | 1 | 5 |
| Russell Rother | 1 | 3 |
| Richard Alvarez | 1 | 3 |
| Philip Jones, M.D. | 1 | 2 |
| David Keiser | 1 | 2 |
| Scott Rollins | 1 | 2 |
| Scott Rollins, Ph.D. | 1 | 2 |
| Rodger McEver, M.D. | 1 | 2 |
| Rodger McEver | 1 | 1 |
| William Paiva, Ph.D. | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.